Finally, looking forward toward translation, the prominent role of HSPGs in tau pathology, and the capacity of glycan-based HS analogs to inhibit tau propagation in cells suggests a potential application of HS based drugs in the treatment of AD and other tauopathies (Alavi Naini and Soussi-Yanicostas, 2018). This evidence concerns the gene MAPT and tauopathy.